We are live on ! Find out more
GC

Grimes & Company Portfolio holdings

AUM $4.62B
1-Year Est. Return 29.71%
This Fund
S&P 500
This Quarter Est. Return
+6.02%
1 Year Est. Return
+29.71%
3 Year Est. Return
+66.17%
5 Year Est. Return
+73.59%
10 Year Est. Return
+287.63%
AUM
$2.37B
AUM Growth
+$453M
Cap. Flow
+$337M
Cap. Flow %
14.21%
Top 10 Hldgs %
52.25%
Holding
309
New
28
Increased
109
Reduced
121
Closed
12

Top Buys

Rank Stock Value
1
VCSH icon
Vanguard Short-Term Corporate Bond ETF
VCSH
+$147M
2
SHV icon
iShares 0-1 Year Treasury Bond ETF
SHV
+$76.7M
3
SUB icon
iShares Short-Term National Muni Bond ETF
SUB
+$65.1M
4
JPST icon
JPMorgan Ultra-Short Income ETF
JPST
+$57.7M
5
IGSB icon
iShares 1-5 Year Investment Grade Corporate Bond ETF
IGSB
+$35.6M

Top Sells

Rank Stock Value
1
IWM icon
iShares Russell 2000 ETF
IWM
+$75M
2
IVV icon
iShares Core S&P 500 ETF
IVV
+$20.3M
3
TER icon
Teradyne
TER
+$10.5M
4
CIEN icon
Ciena
CIEN
+$8.25M
5
XLV icon
State Street Health Care Select Sector SPDR ETF
XLV
+$6.7M

Sector Composition

Rank Sector Weight
1 Technology 10.08%
2 Healthcare 7.83%
3 Financials 5.02%
4 Industrials 4.83%
5 Consumer Discretionary 2.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRF
276
Cornerstone Total Return Fund
CRF
$1.16B
$125K 0.01%
17,973
+1,347
+8% +$10.5K
VBIV
277
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$114K ﹤0.01%
9,679
+49
+0.5% +$864
ISPC icon
278
iSpecimen
ISPC
$2.85M
$90.2K ﹤0.01%
82
– –
MRSN
279
DELISTED
Mersana Therapeutics
MRSN
$89.5K ﹤0.01%
611
+4
+0.7% +$676
VOR icon
280
Vor Biopharma
VOR
$1.15B
$72.2K ﹤0.01%
+543
New +$53.7K
METV icon
281
Roundhill Ball Metaverse ETF
METV
$213M
$71.9K ﹤0.01%
+10,009
New +$74.8K
NAK
282
Northern Dynasty Minerals
NAK
$818M
$70.4K ﹤0.01%
318,950
– –
HRTX icon
283
Heron Therapeutics
HRTX
$97.4M
$39.4K ﹤0.01%
15,760
– –
RBBN icon
284
Ribbon Communications
RBBN
$373M
$28K ﹤0.01%
10,030
– –
REKR icon
285
Rekor Systems
REKR
$88.1M
$24K ﹤0.01%
+20,000
New +$19.4K
FUBO icon
286
FuboTV Inc
FUBO
$286M
$17.4K ﹤0.01%
833
– –
OTLK icon
287
Outlook Therapeutics
OTLK
$176M
$10.8K ﹤0.01%
500
– –
ESML icon
288
iShares ESG Aware MSCI USA Small-Cap ETF
ESML
$2.86B
– –
-19,536
Closed -$599K
FTSM icon
289
First Trust Enhanced Short Maturity ETF
FTSM
$6.5B
– –
-44,371
Closed -$2.63M
IBB icon
290
iShares Biotechnology ETF
IBB
$9.19B
– –
-2,080
Closed -$243K
ICSH icon
291
iShares Ultra Short Duration Bond Active ETF
ICSH
$8.12B
– –
-42,387
Closed -$2.12M
ITRM
292
DELISTED
Iterum Therapeutics
ITRM
– –
-14,641
Closed -$24K
LNC icon
293
Lincoln National
LNC
$8.78B
– –
-6,228
Closed -$273K
OGEN icon
294
Oragenics
OGEN
$2.35M
– –
-7
Closed -$3K
SCHG icon
295
Schwab US Large-Cap Growth ETF
SCHG
$61B
– –
-23,332
Closed -$326K
XLF icon
296
State Street Financial Select Sector SPDR ETF
XLF
$57.7B
– –
-42,597
Closed -$1.29M
FLG
297
Flagstar Bank National Association
FLG
$5.95B
– –
-9,390
Closed -$240K
ABMD
298
DELISTED
Abiomed Inc
ABMD
– –
-1,014
Closed -$249K
AVEO
299
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
– –
-19,380
Closed -$159K
8 9 10 11
12

Similar funds

DWM
Dakota Wealth Management Palm Beach Gardens, Florida $4.62B AUM 33.09% 1-Year Est. Return
ANTB
AMG National Trust Bank Greenwood Village, Colorado $4.61B AUM 19.2% 1-Year Est. Return
VCM
Voleon Capital Management Berkeley, California $4.64B AUM 38.78% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
AG
AlTi Global New York $4.6B AUM 22.54% 1-Year Est. Return
SCM
Smead Capital Management Phoenix, Arizona $4.6B AUM 27.56% 1-Year Est. Return
ASC
Atalanta Sosnoff Capital New York $4.66B AUM 41.34% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Grimes & Company's Q4 2022 Portfolio in Review

As of Q4 2022, Grimes & Company held 309 positions worth $2.37B, up 24% from $1.92B the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Grimes & Company deployed $337M of net new capital in Q4 2022, opening 28 new positions and adding to 109 existing holdings. Its largest new stake was Vanguard Short-Term Corporate Bond ETF: 1,968,274 shares worth $148M.

By sector, the portfolio is most concentrated in Technology at 10% of assets, down from 12% a quarter earlier, followed by Healthcare and Financials.

On the sell side, the largest reduction was iShares Russell 2000 ETF, an estimated $75M trimmed.

  • Grimes & Company's largest Q4 2022 buy was Vanguard Short-Term Corporate Bond ETF: 1,968,274 shares worth $148M.
  • Grimes & Company added most to iShares 0-1 Year Treasury Bond ETF in Q4 2022, an estimated $76.7M increase.
  • Grimes & Company's biggest Q4 2022 reduction was iShares Russell 2000 ETF, cutting an estimated $75M.
  • Grimes & Company fully exited First Trust Enhanced Short Maturity ETF in Q4 2022, selling an estimated $2.63M.
  • Grimes & Company's ten largest holdings make up 52% of its $2.37B portfolio in Q4 2022.
  • Grimes & Company opened 28 new positions and closed 12 in Q4 2022.
  • Grimes & Company's portfolio value rose 24% quarter-over-quarter to $2.37B.

Based on Grimes & Company's 13F filing for Q4 2022, filed 25 Jan 2023.